European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Zika Preparedness Latin American Network

Descrizione del progetto

Creazione di una rete per la preparazione e la risposta al virus Zika

I focolai epidemici del virus Zika (ZIKV) nel 2015 e 2016 hanno richiamato l’attenzione sull’associazione di questo virus a complicazioni congenite e neurologiche. Sebbene il numero di casi sia diminuito, le autorità sanitarie considerano ancora lo ZIKV un problema serio che richiede approfondimenti ulteriori. Attraverso la collaborazione con partner globali, il progetto ZikaPLAN, finanziato dall’UE, intende colmare le lacune nella ricerca e fornire strategie per la prevenzione dello ZIKV. A tal fine, condurrà studi clinici per identificare la capacità di replicazione del virus e i fattori di rischio della sindrome congenita e dei disturbi neurologici, svilupperà test diagnostici e modelli vaccinali specifici per lo ZIKV, esaminerà i rischi di diffusione geografica e stilerà linee guida informate per mitigare le future epidemie. Nel complesso, ZikaPLAN darà vita a una rete sostenibile per la preparazione e la risposta a questa malattia.

Obiettivo

The ZikaPLAN initiative combines the strengths of 25 partners in Latin America, North America, Africa, Asia, and various centres in Europe to address the urgent research gaps (WP 1-8) in Zika, identifying short-and long term solutions (WP 9-10) and building a sustainable Latin-American EID Preparedness and Response capacity (WP 11-12). 

We will conduct clinical studies to further refine the full spectrum and risk factors of congenital Zika syndrome (including neurodevelopmental milestones in the first 3 years of life), and delineate neurological complications associated with Zika due to direct neuroinvasion and immune-mediated responses. Laboratory based research to unravel neurotropism, investigate the role of sexual transmission, determinants of severe disease, and viral fitness will envelop the clinical studies.

Burden of disease and modelling studies will assemble a wealth of data including a longitudinal cohort study of 17,000 subjects aged 2-59 in 14 different geographic locations in Brazil over 3 years. Data driven vector control and vaccine modelling as well as risk assessments on geographic spread of Zika will form the foundation for evidence-informed policies.
The Platform for Diagnostics Innovation and Evaluation will develop novel ZIKV diagnostic tests in accordance with WHO Target Product Profiles. Our global network of laboratory and clinical sites with well-characterized specimens is set out to accelerate the evaluation of the performance of such tests. 

Based on qualitative research, we will develop supportive, actionable messages to affected communities, and develop novel personal protective measures. Our final objective is for the Zika outbreak response effort to grow into a sustainable Latin-American network for emerging infectious diseases research preparedness. To this end we will engage in capacity building in laboratory and clinical research, collaborate with existing networks to share knowledge and tackle regulatory and other bottlenecks.

Invito a presentare proposte

H2020-SC1-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2016-RTD-Zika

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

UMEA UNIVERSITET
Contribution nette de l'UE
€ 1 680 618,75
Indirizzo
UNIVERSITETOMRADET
901 87 Umea
Svezia

Mostra sulla mappa

Regione
Norra Sverige Övre Norrland Västerbottens län
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 680 618,75

Partecipanti (27)